This study explores the effectiveness of a drug called **VIB4920** for people with active **lupus nephritis (LN)**, which is a kidney problem caused by lupus, a disease where the immune system attacks healthy parts of the body. The study is double-blind, meaning neither the participants nor the doctors know who is receiving the actual drug or a placebo (a substance with no treatment effect). Participants will also receive other medications like **mycophenolate mofetil (MMF)** and **prednisone** to help with their condition. Key Points to Consider: - The study lasts for about 60 weeks with different treatments given at specific weeks. - Participants will need to visit the clinic multiple times for treatment and check-ups. - Eligibility requires being 18 or older and having certain kidney test results. This study is not for everyone. Those who cannot follow the study rules or have certain health conditions, like recent infections or pregnancy, cannot participate. Participants should discuss potential risks and benefits with their doctor before deciding to join.